Robert Harrington to Stroke
This is a "connection" page, showing publications Robert Harrington has written about Stroke.
Connection Strength
2.139
-
Call to Action: Rural Health: A Presidential Advisory From the American Heart Association and American Stroke Association. Circulation. 2020 03 10; 141(10):e615-e644.
Score: 0.278
-
Prehospital Phase of Acute Stroke Care: Guideline and Policy Considerations as Science and Evidence Rapidly Evolve. Stroke. 2019 07; 50(7):1637-1639.
Score: 0.264
-
Metabolic syndrome is not associated with increased mortality or cardiovascular risk in nondiabetic patients with a new diagnosis of coronary artery disease. Circ Cardiovasc Qual Outcomes. 2010 Mar; 3(2):165-72.
Score: 0.139
-
External applicability of the Effect of ticagrelor on Health Outcomes in diabEtes Mellitus patients Intervention Study (THEMIS) trial: An analysis of patients with diabetes and coronary artery disease in the REduction of Atherothrombosis for Continued Health (REACH) registry. Int J Cardiol. 2023 Jan 01; 370:51-57.
Score: 0.084
-
Balance of benefit and risk of ticagrelor in patients with diabetes and stable coronary artery disease according to bleeding risk assessment with the CRUSADE score: Data from THEMIS and THEMIS PCI. Am Heart J. 2022 07; 249:23-33.
Score: 0.080
-
Rationale and Design of the Aspirin Dosing-A Patient-Centric Trial Assessing Benefits and Long-term Effectiveness (ADAPTABLE) Trial. JAMA Cardiol. 2020 05 01; 5(5):598-607.
Score: 0.070
-
In patients with stable coronary heart disease, low-density lipoprotein-cholesterol levels < 70 mg/dL and glycosylated hemoglobin A1c
View in: PubMed
Score: 0.070
Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke. Stroke. 2019 12; 50(12):3331-3332.
Score: 0.068
Site Variation and Outcomes for Antithrombotic Therapy in Atrial Fibrillation Patients After Percutaneous Coronary Intervention. Circ Cardiovasc Interv. 2019 08; 12(8):e007604.
Score: 0.067
Stroke Outcomes With Vorapaxar Versus Placebo in Patients With Acute Coronary Syndromes: Insights From the TRACER Trial. J Am Heart Assoc. 2018 12 18; 7(24):e009609.
Score: 0.064
N-terminal pro-B-type natriuretic peptide and the risk of stroke among patients hospitalized with acute heart failure: an APEX trial substudy. J Thromb Thrombolysis. 2017 Nov; 44(4):457-465.
Score: 0.059
Apixaban following acute coronary syndromes in patients with prior stroke: Insights from the APPRAISE-2 trial. Am Heart J. 2018 03; 197:1-8.
Score: 0.059
Differential occurrence, profile, and impact of first recurrent cardiovascular events after an acute coronary syndrome. Am Heart J. 2017 May; 187:194-203.
Score: 0.057
Impact of Cerebrovascular Events Older Than One Year on Ischemic and Bleeding Outcomes With Cangrelor in Percutaneous Coronary Intervention. Circ Cardiovasc Interv. 2017 01; 10(1).
Score: 0.056
Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban). Circulation. 2017 02 14; 135(7):648-655.
Score: 0.055
Acquisition, Analysis, and Sharing of Data in 2015 and Beyond: A Survey of the Landscape: A Conference Report From the American Heart Association Data Summit 2015. J Am Heart Assoc. 2015 Nov 05; 4(11).
Score: 0.052
Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. Am Heart J. 2014 Nov; 168(5):682-9.
Score: 0.047
Response to letter regarding article, "Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials". Stroke. 2013 Aug; 44(8):e95-6.
Score: 0.044
Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials. Stroke. 2013 May; 44(5):1477-9.
Score: 0.043
Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial. Circulation. 2012 Feb 28; 125(8):978-86.
Score: 0.040
Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2011 Aug 02; 124(5):544-54.
Score: 0.038
Relation between aspirin dose, all-cause mortality, and bleeding in patients with recent cerebrovascular or coronary ischemic events (from the BRAVO Trial). Am J Cardiol. 2008 Nov 15; 102(10):1285-90.
Score: 0.031
Effects of pyridoxal-5'-phosphate (MC-1) in patients undergoing high-risk coronary artery bypass surgery: results of the MEND-CABG randomized study. J Thorac Cardiovasc Surg. 2007 Jun; 133(6):1604-11.
Score: 0.029
Creatine kinase-MB elevation after coronary artery bypass grafting surgery in patients with non-ST-segment elevation acute coronary syndromes predict worse outcomes: results from four large clinical trials. Eur Heart J. 2007 Feb; 28(4):425-32.
Score: 0.028
Statin use and sex-specific stroke outcomes in patients with vascular disease. Stroke. 2006 Jun; 37(6):1427-31.
Score: 0.027
Comparative Effectiveness of Aspirin Dosing in Cardiovascular Disease. N Engl J Med. 2021 05 27; 384(21):1981-1990.
Score: 0.019
Ticagrelor in Patients with Stable Coronary Disease and Diabetes. N Engl J Med. 2019 Oct 03; 381(14):1309-1320.
Score: 0.017
Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial. Lancet. 2019 Sep 28; 394(10204):1169-1180.
Score: 0.017
Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study. Clin Cardiol. 2019 May; 42(5):498-505.
Score: 0.016
Reduction of Cardiovascular Mortality and Ischemic Events in Acute Medically Ill Patients. Circulation. 2019 02 26; 139(9):1234-1236.
Score: 0.016
Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease. J Am Heart Assoc. 2016 06 21; 5(6).
Score: 0.013
Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial. Am Heart J. 2016 08; 178:176-84.
Score: 0.013
Validation of BARC Bleeding Criteria in Patients With Acute Coronary Syndromes: The TRACER Trial. J Am Coll Cardiol. 2016 May 10; 67(18):2135-2144.
Score: 0.013
Impact of glycoprotein IIb/IIIa inhibitors on the efficacy and safety of ticagrelor compared with clopidogrel in patients with acute coronary syndromes: Analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Am Heart J. 2016 Jul; 177:1-8.
Score: 0.013
Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxar. Catheter Cardiovasc Interv. 2016 Aug; 88(2):163-73.
Score: 0.013
Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial. Am Heart J. 2014 Dec; 168(6):869-77.e1.
Score: 0.012
Predictors of contemporary coronary artery bypass grafting outcomes. J Thorac Cardiovasc Surg. 2014 Dec; 148(6):2720-6.e1-2.
Score: 0.012
Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med. 2014 May 01; 370(18):1702-11.
Score: 0.012
Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial. Eur Heart J Acute Cardiovasc Care. 2014 Sep; 3(3):246-56.
Score: 0.012
Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome). J Am Coll Cardiol. 2014 Mar 25; 63(11):1048-57.
Score: 0.011
A multicenter, randomized, active-controlled study to investigate the efficacy and safety of intravenous ferric carboxymaltose in patients with iron deficiency anemia. Transfusion. 2014 Feb; 54(2):306-15.
Score: 0.011
Effect of adenosine-regulating agent acadesine on morbidity and mortality associated with coronary artery bypass grafting: the RED-CABG randomized controlled trial. JAMA. 2012 Jul 11; 308(2):157-64.
Score: 0.010
A randomized, double-blind, active-controlled phase 2 trial to evaluate a novel selective and reversible intravenous and oral P2Y12 inhibitor elinogrel versus clopidogrel in patients undergoing nonurgent percutaneous coronary intervention: the INNOVATE-PCI trial. Circ Cardiovasc Interv. 2012 Jun; 5(3):336-46.
Score: 0.010
Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial. Eur Heart J. 2011 Dec; 32(23):2933-44.
Score: 0.010
Apixaban with antiplatelet therapy after acute coronary syndrome. N Engl J Med. 2011 Aug 25; 365(8):699-708.
Score: 0.010
Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009 Sep 10; 361(11):1045-57.
Score: 0.008
Prior polyvascular disease: risk factor for adverse ischaemic outcomes in acute coronary syndromes. Eur Heart J. 2009 May; 30(10):1195-202.
Score: 0.008
Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet. 2004 Aug 21-27; 364(9435):675-84.
Score: 0.006
Aspirin dose and six-month outcome after an acute coronary syndrome. J Am Coll Cardiol. 2004 Mar 17; 43(6):972-8.
Score: 0.006